RxDoctor Payments Data

Leo Ginns, MD

Pulmonary Disease · Boston, MANPI 1144211772

Payments from drug & device makers

What this record shows

That places this record below the midpoint for pulmonary disease clinicians in MA, where the typical reported total is $291.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$668,178in research payments, 2019–2025

Across 79 payments — averaging $8457.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$450K
  • Roche Products Limited$205K
  • Biogen$13K

How this compares

$0 in reported general payments places this provider in the 15th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$62,982
Medicare patients
409
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate16$213,347
Pirfenidone40$121,141
Incruse ElliptaUmeclidinium Bromide14$8,179
Wixela InhubFluticasone Propion/Salmeterol15$2,321
Albuterol Sulfate HfaAlbuterol Sulfate24$904
Prednisone25$167

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →